SNDX Stock Analysis: Syndax Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.573m USD | 12M Return: 21.1% | US87164F1057 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 30.4M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Syndax Pharmaceuticals (NASDAQ: SNDX) is a New York-based commercial-stage biopharmaceutical company, incorporated in 2005, that develops oncology therapies. It markets two lead products: Revuforj (revumenib), a menin inhibitor for relapsed or refractory acute leukemia, and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor (CSF-1R) blocking antibody for chronic graft-versus-host disease. The pipeline expands revumenib into additional acute myeloid leukemia (AML) indications and metastatic colorectal cancer, explores axatilimab in idiopathic pulmonary fibrosis, and includes Entinostat, a Class I HDAC inhibitor that is licensed to Eddingpharm International for development and commercialization in certain markets.
Operating in the biotechnology sub-industry of the health care sector, Syndax uses a targeted-therapy model, building a portfolio around small-molecule inhibitors and monoclonal antibodies designed against specific oncogenic drivers and immune-modulating pathways. As a commercial-stage small-cap biotech, it supplements its in-house development with out-licensing partnerships to extend geographic reach and share clinical and commercial risk.
- Revuforj revenue ramp accelerates in relapsed acute leukemia
- Niktimvo launch uptake scales in chronic graft-versus-host disease
- Revumenib label expansion into mNPM1 AML and combinations
| Net Income: -220.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.24 > 0.02 and ΔFCF/TA 23.64 > 1.0 |
| NWC/Revenue: 228.3% < 20% (prev 535.5%; Δ -307.2% < -1%) |
| CFO/TA -0.31 > 3% & CFO -220.6m > Net Income -220.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (89.0m) vs 12m ago 3.07% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 38.78% > 50% (prev 13.11%; Δ 25.66% > 0%) |
| Interest Coverage Ratio: -2.27 > 6 (EBIT TTM -194.2m / Interest Expense TTM 85.5m) |
| A: 0.82 (Total Current Assets 675.0m - Total Current Liabilities 99.7m) / Total Assets 703.7m |
| B: -2.27 (Retained Earnings -1.60b / Total Assets 703.7m) |
| C: -0.30 (EBIT TTM -194.2m / Avg Total Assets 649.9m) |
| D: 0.02 (Book Value of Equity 15.1m / Total Liabilities 688.6m) |
| Altman-Z'' = -4.03 = D |
| DSRI: 0.58 (Receivables 70.2m/37.4m, Revenue 252.0m/78.2m) |
| GMI: 0.99 (GM 96.17% / 97.47%) |
| AQI: 0.36 (AQ_t 0.04 / AQ_t-1 0.11) |
| SGI: 3.22 (Revenue 252.0m / 78.2m) |
| TATA: -0.00 (NI -220.8m - CFO -220.6m) / TA 703.7m) |
| Beneish M = -2.17 (Cap -4..+1) = BB |
As of September 26, 2026, the stock is trading at USD 18.20 with a total of 1,315,122 shares traded. Over the past week, the price has changed by +3.29%, over one month by -8.63%, over three months by -8.13% and over the past year by +21.09%.
Current recommended Stop Loss: 16.30 (which is 10.4% or 2.2 ATR below the current price).
Syndax Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy SNDX.
- StrongBuy: 9
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 37.6 | 106.3% |
P/S = 6.1895
P/B = 104.4135
Revenue TTM = 252.0m USD
EBIT TTM = -194.2m USD
EBITDA TTM = -194.2m USD
Long Term Debt = 588.1m USD (from longTermDebt, last quarter)
Short Term Debt = 506k USD (from shortTermDebt, last quarter)
Debt = 590.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.27m
Net Debt = 42.8m USD (calculated: Debt 590.6m - CCE 547.9m)
Enterprise Value = 1.62b USD (1.57b + Debt 590.6m - CCE 547.9m)
Interest Coverage Ratio = -2.27 (Ebit TTM -194.2m / Interest Expense TTM 85.5m)
EV/FCF = -9.41x (Enterprise Value 1.62b / FCF TTM -171.7m)
FCF Yield = -10.63% (FCF TTM -171.7m / Enterprise Value 1.62b)
FCF Margin = -68.15% (FCF TTM -171.7m / Revenue TTM 252.0m)
Net Margin = -87.60% (Net Income TTM -220.8m / Revenue TTM 252.0m)
Gross Margin = unknown ((Revenue TTM 252.0m - Cost of Revenue TTM 6.37m) / Revenue TTM)
Tobins Q-Ratio = 2.30 (Enterprise Value 1.62b / Total Assets 703.7m)
Interest Expense / Debt = 14.48% (Interest Expense 85.5m / Debt 590.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -153.4m (EBIT -194.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.46 (Total Current Assets 675.0m / Total Current Liabilities 104.6m)
Debt / Equity = 39.12 (Debt 590.6m / totalStockholderEquity, last quarter 15.1m)
Debt / EBITDA = -0.22 (negative EBITDA) (Net Debt 42.8m / EBITDA -194.2m)
Debt / FCF = -0.25 (negative FCF - burning cash) (Net Debt 42.8m / FCF TTM -171.7m)
Total Stockholder Equity = 59.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.97% (Net Income -220.8m / Total Assets 703.7m)
RoE = -372.9% (Net Income TTM -220.8m / Total Stockholder Equity 59.2m)
RoCE = -30.00% (EBIT -194.2m / Capital Employed (Equity 59.2m + L.T.Debt 588.1m))
RoIC = -25.92% (negative operating profit) (NOPAT -153.4m / Invested Capital 591.9m)
WACC = 9.51% (E(1.57b)/V(2.16b) * Re(8.78%) + D(590.6m)/V(2.16b) * Rd(14.48%) * (1-Tc(0.21)))
Discount Rate = 8.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.34 | Cagr: 1.95%
[DCF] Fair Price = unknown (Cash Flow -171.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.28 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.22 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.47 | Chg30d=-21.06% | Revisions=-25% | Analysts=10
EPS current Year (2026-12-31): EPS=-1.93 | Chg30d=-14.95% | Revisions=-42% | GrowthEPS=+41.2% | GrowthRev=+83.4%
EPS next Year (2027-12-31): EPS=-0.82 | Chg30d=-60.17% | Revisions=-46% | GrowthEPS=+57.8% | GrowthRev=+46.5%
[Analyst] Revisions Ratio: -45% (up=7, down=21)